Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > comgrats

<< Previous

Bullboard Posts

Next >>

Comment by MrMugsyon Nov 22, 2023 11:19pm

207 Views

Post# 35749554

RE:RE:RE:RE:RE:RE:RE:RE:comgrats

I've been clear that I don't follow general percentages of success when it comes to OTENA - nor did I ever give up on chronic. If you think there is only one path or that daily chronic is all we have after acute ... that's just not true ... in my mind anyway.

For example - if you had no choice - you could run a strange combination of naproxen and OTENA for improved safety. The paths are endless ... in my mind !

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario